Literature DB >> 24774670

Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease.

Marta Olivares1, Gemma Castillejo2, Vicente Varea3, Yolanda Sanz1.   

Abstract

Interactions between the immune system and the intestinal microbiota may play a role in coeliac disease (CD). In the present study, the potential effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed CD were evaluated. A double-blind, randomised, placebo-controlled trial was conducted in thirty-three children who received a capsule containing either B. longum CECT 7347 (10⁹ colony-forming units) or placebo (excipients) daily for 3 months together with a gluten-free diet (GFD). Outcome measures (baseline and post-intervention) included immune phenotype of peripheral blood cells, serum cytokine concentration, faecal secretory IgA (sIgA) content, anthropometric parameters and intestinal microbiota composition. Comparisons between the groups revealed greater height percentile increases (P= 0·048) in the B. longum CECT 7347 group than in the placebo group, as well as decreased peripheral CD3⁺ T lymphocytes (P= 0·004) and slightly reduced TNF-α concentration (P= 0·067). Within-group comparisons of baseline and final values did not reveal any differences in T lymphocytes and cytokines in the placebo group, while decreased CD3⁺ (P =0·013) and human leucocyte antigen (HLA)-DR⁺ T lymphocytes (P =0·029) and slightly reduced TNF-α concentration (P= 0·085) were detected in the B. longum CECT 7347 group. Comparison between the groups showed that the administration of B. longum CECT 7347 reduced the numbers of the Bacteroides fragilis group (P= 0·020) and the content of sIgA in stools (P= 0·011) compared with the administration of placebo. Although this is a first exploratory intervention with limitations, the findings suggest that B. longum CECT 7347 could help improve the health status of CD patients who tend to show alterations in gut microbiota composition and a biased immune response even on a GFD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24774670     DOI: 10.1017/S0007114514000609

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  37 in total

1.  A Commensal Bifidobacterium longum Strain Prevents Gluten-Related Immunopathology in Mice through Expression of a Serine Protease Inhibitor.

Authors:  J L McCarville; J Dong; A Caminero; M Bermudez-Brito; J Jury; J A Murray; S Duboux; M Steinmann; M Delley; M Tangyu; P Langella; A Mercenier; G Bergonzelli; E F Verdu
Journal:  Appl Environ Microbiol       Date:  2017-09-15       Impact factor: 4.792

Review 2.  Risk and safety of probiotics.

Authors:  Shira Doron; David R Snydman
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

Review 3.  Gut Microbiota and Celiac Disease.

Authors:  Giovanni Marasco; Anna Rita Di Biase; Ramona Schiumerini; Leonardo Henry Eusebi; Lorenzo Iughetti; Federico Ravaioli; Eleonora Scaioli; Antonio Colecchia; Davide Festi
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

4.  Administration of Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease.

Authors:  Martina Klemenak; Jernej Dolinšek; Tomaž Langerholc; Diana Di Gioia; Dušanka Mičetić-Turk
Journal:  Dig Dis Sci       Date:  2015-07-02       Impact factor: 3.199

Review 5.  Novel players in coeliac disease pathogenesis: role of the gut microbiota.

Authors:  Elena F Verdu; Heather J Galipeau; Bana Jabri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

Review 6.  Dysbiosis a risk factor for celiac disease.

Authors:  Anamaria Girbovan; Genel Sur; Gabriel Samasca; Iulia Lupan
Journal:  Med Microbiol Immunol       Date:  2017-02-15       Impact factor: 3.402

7.  Novel Drug Therapeutics in Celiac Disease: A Pipeline Review.

Authors:  Sanskriti Varma; Suneeta Krishnareddy
Journal:  Drugs       Date:  2022-10-17       Impact factor: 11.431

Review 8.  Current and emerging therapies for coeliac disease.

Authors:  Laura Kivelä; Alberto Caminero; Daniel A Leffler; Maria Ines Pinto-Sanchez; Jason A Tye-Din; Katri Lindfors
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-20       Impact factor: 46.802

9.  Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial.

Authors:  Vicente Navarro-López; Ana Ramírez-Boscá; Daniel Ramón-Vidal; Beatriz Ruzafa-Costas; Salvador Genovés-Martínez; Empar Chenoll-Cuadros; Miguel Carrión-Gutiérrez; José Horga de la Parte; David Prieto-Merino; Francisco M Codoñer-Cortés
Journal:  JAMA Dermatol       Date:  2018-01-01       Impact factor: 10.282

10.  Fecal and Duodenal Microbiota in Pediatric Celiac Disease.

Authors:  Diyora Abdukhakimova; Kuanysh Dossybayeva; Dimitri Poddighe
Journal:  Front Pediatr       Date:  2021-04-22       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.